Registered title, quoted from ClinicalTrials.gov
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 19 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 19
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
- Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
- Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
- Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07700667, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), who are ineligible for curative-intent therapies:
Inclusion criterion 2
Safety run-in phase (Cohort 1, 2 and 3): received no more than 1 prior line of systemic therapy for locally advanced or metastatic ESCC.
Inclusion criterion 3
Safety run-in phase (Cohort 4) and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.
Inclusion criterion 4
Unresolved to grade ≤ 1 of prior anti-cancer treatment toxicities criteria per CTCAE v6.0.
Exclusion criterion 11
Previously received B7-H3-targeted agents, including antibody, antibody-drug conjugate (ADC), and other agents.
Exclusion criterion 12
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Inclusion criterion 7
Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Inclusion criterion 6
Pregnant or lactating women.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07700667, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years and ≤75 years
- Histologically or cytologically confirmed unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), who are ineligible for curative-intent therapies:
- Safety run-in phase (Cohort 1, 2 and 3): received no more than 1 prior line of systemic therapy for locally advanced or metastatic ESCC.
- Safety run-in phase (Cohort 4) and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.
- Participants are required to provide tumor tissue samples for biomarker analysis.
- Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 12 weeks.
Exclusion Criteria:
- Histology or cytology confirms the presence of concurrent adenocarcinoma components.
- Leptomeningeal, brainstem, spinal, spinal cord compression, or active CNS metastases.
- Risk of esophagotracheal/esophagopleural fistula, or symptomatic invasion/compression of vital organs/major blood vessels.
- Active autoimmune disease requiring systemic therapy within past 2 years.
- Weight loss ≥10% within 4 weeks prior to the first dose, or Nutritional Risk Index (NRI) < 83.5.
- Severe infection within 4 weeks or active infection requiring systemic treatment within 2 weeks pre-dose.
- Uncontrolled comorbidities (e.g., decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, Grade ≥2 peripheral neuropathy).
- Cardiovascular/cerebrovascular events within 6 months pre-dose (e.g., Myocardial Infarction, unstable angina, acute/persistent ischemia, Grade 3/4 Heart Failure, symptomatic/uncontrolled arrhythmia, Cerebrovascular Accident, Transient Ischemic Attack).
- Uncontrolled hypertension, diabetes, or recurrent pleural/pericardial/abdominal effusion requiring drainage.
- History of interstitial lung disease (ILD) or noninfectious pneumonitis that require steroid treatment, or currently has ILD/noninfectious pneumonitis.
- Unresolved to grade ≤ 1 of prior anti-cancer treatment toxicities criteria per CTCAE v6.0.
- Previously received B7-H3-targeted agents, including antibody, antibody-drug conjugate (ADC), and other agents.
- Previously received any agent containing a topoisomerase I inhibitor (including chemotherapy and antibody-drug conjugate(ADC)).
- Pregnant or lactating women.
Quoted from ClinicalTrials.gov, NCT07700667, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07700667, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.